#1 Clinical Trials Search in Europe

Eftilagimod Alfa

Eftilagimod Alfa, also known as IMP321 or efti, is an innovative immunotherapy drug currently being studied in clinical trials for various types of cancer. This article explores the use of Eftilagimod Alfa in combination with other treatments, its potential benefits, and ongoing research efforts to improve cancer treatment outcomes.

Table of Contents

What is Eftilagimod Alpha?

Eftilagimod alpha, also known as IMP321 or efti, is an innovative immunotherapy drug currently being studied for its potential in treating various types of cancer[1]. It is classified as a soluble LAG-3 protein, which means it’s a substance that can interact with the immune system to help fight cancer cells[2].

How Does It Work?

Eftilagimod alpha works as an APC activator and MHC II agonist[1]. To break this down for patients:

  • APC activator: APCs, or Antigen Presenting Cells, are crucial components of our immune system. They help identify harmful substances (like cancer cells) and present them to other immune cells for destruction. Eftilagimod alpha activates these cells, potentially boosting the immune response against cancer.
  • MHC II agonist: MHC II molecules are proteins found on the surface of certain immune cells. They play a key role in helping the immune system recognize foreign substances. As an agonist, eftilagimod alpha enhances the activity of these molecules, potentially improving the immune system’s ability to detect and fight cancer cells.

This mechanism of action makes eftilagimod alpha a promising candidate for combination therapies, particularly with other immunotherapy drugs like pembrolizumab (Keytruda)[4].

What Conditions Does Eftilagimod Alpha Treat?

Eftilagimod alpha is being studied for its potential in treating several types of cancer, including:

  • Head and Neck Squamous Cell Carcinoma (HNSCC): A type of cancer that begins in the squamous cells that line the mouth, nose, and throat[1].
  • Non-Small Cell Lung Cancer (NSCLC): The most common type of lung cancer[4].
  • Soft Tissue Sarcoma: A rare type of cancer that begins in the tissues that connect, support, and surround other body structures[2].
  • Metastatic Breast Cancer: Breast cancer that has spread to other parts of the body[3].
  • Melanoma: A serious type of skin cancer[5].

Current Clinical Trials

Eftilagimod alpha is currently being tested in several clinical trials:

  • TACTI-003: A phase II trial studying the combination of eftilagimod alpha with pembrolizumab in patients with recurrent or metastatic head and neck cancer[1].
  • EFTISARC-NEO: A phase II trial evaluating eftilagimod alpha with pembrolizumab and radiotherapy in patients with soft tissue sarcomas[2].
  • AIPAC-002: A phase Ib study testing eftilagimod alpha with paclitaxel in hormone receptor-positive metastatic breast cancer[3].
  • TACTI-002: A phase II study of eftilagimod alpha with pembrolizumab in non-small cell lung cancer and head and neck cancer[4].
  • A phase I study of eftilagimod alpha with pembrolizumab in unresectable or metastatic melanoma[5].

How is Eftilagimod Alpha Administered?

Eftilagimod alpha is typically administered as a subcutaneous injection (an injection under the skin). The dosage and frequency can vary depending on the specific clinical trial and condition being treated. For example:

  • In some trials, it’s given as a 30 mg injection every 2 or 3 weeks[1].
  • In others, it might be given as a 20 mg injection every 2 weeks[2].

It’s important to note that the drug is often given in combination with other cancer treatments, such as chemotherapy or other immunotherapy drugs[3][4].

Potential Side Effects

As with any medical treatment, eftilagimod alpha may cause side effects. The full range of potential side effects is still being studied in clinical trials. These trials are closely monitoring the frequency, severity, and duration of any adverse events[1][2]. Patients participating in these trials are carefully monitored for any unexpected reactions.

Future Prospects

The ongoing clinical trials are evaluating various aspects of eftilagimod alpha’s performance, including:

  • Its effectiveness in shrinking tumors or slowing cancer growth[1][4].
  • How long patients survive without their cancer getting worse (progression-free survival)[1][5].
  • Overall survival rates[1][2].
  • Its safety profile and how well patients tolerate the treatment[3].

The results of these trials will help determine the future role of eftilagimod alpha in cancer treatment. If successful, it could provide a new option for patients with various types of cancer, potentially improving their outcomes and quality of life.

Aspect Details
Drug Name Eftilagimod Alfa (IMP321, efti)
Drug Type Soluble LAG-3 fusion protein, APC activator, MHC II agonist
Administration Subcutaneous injection, typically 20-30 mg every 2-3 weeks
Cancer Types Studied HNSCC, NSCLC, Soft Tissue Sarcomas, Metastatic Breast Cancer, Melanoma
Combination Therapies Pembrolizumab, Paclitaxel, Radiotherapy
Primary Study Objectives Safety, Tolerability, Efficacy, Recommended Phase 2 Dose
Secondary Outcomes Overall Survival, Progression-Free Survival, Objective Response Rate
Trial Phases Phase I, Phase II
Notable Features Often combined with other immunotherapies or chemotherapies, Potential for use in neoadjuvant settings

FAQ

  • What is Eftilagimod Alfa? Eftilagimod Alfa is a soluble LAG-3 fusion protein that acts as an APC activator and MHC II agonist. It is being studied as an immunotherapy drug to enhance the body's immune response against cancer cells.
  • What types of cancer are being studied with Eftilagimod Alfa? Clinical trials are investigating Eftilagimod Alfa for various cancers, including head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), soft tissue sarcomas, metastatic breast cancer, and melanoma.
  • How is Eftilagimod Alfa administered? Eftilagimod Alfa is typically administered subcutaneously (under the skin) at doses ranging from 20 to 30 mg, usually every 2 or 3 weeks, depending on the specific trial protocol.
  • What other drugs is Eftilagimod Alfa combined with in clinical trials? Eftilagimod Alfa is often combined with other immunotherapy drugs, such as pembrolizumab (Keytruda), or chemotherapy drugs like paclitaxel. Some trials also combine it with radiotherapy.
  • What are the primary goals of these clinical trials? The main objectives of these trials are to assess the safety, tolerability, and efficacy of Eftilagimod Alfa in combination with other treatments. Researchers are also studying its effects on overall survival, progression-free survival, and objective response rates in cancer patients.

Ongoing Clinical Trials on Eftilagimod Alfa

  • Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Germany Greece +9

  • Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark Germany Romania Spain

  • Study on Pembrolizumab and Eftilagimod Alfa with Radiotherapy for Patients with Resectable Soft Tissue Sarcomas

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Poland

  • Study of Eftilagimod Alpha and Paclitaxel in Patients with HER2-Negative/Low Metastatic Breast Cancer

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Spain

Glossary

  • LAG-3: Lymphocyte Activation Gene-3, a protein involved in regulating immune responses.
  • APC: Antigen Presenting Cell, a type of immune cell that helps activate other immune cells against specific threats.
  • MHC II: Major Histocompatibility Complex Class II, a molecule on the surface of certain immune cells that helps present antigens to other immune cells.
  • HNSCC: Head and Neck Squamous Cell Carcinoma, a type of cancer that affects the mouth, nose, and throat regions.
  • NSCLC: Non-Small Cell Lung Cancer, a common type of lung cancer.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Neoadjuvant: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • Pembrolizumab: An immunotherapy drug that helps the immune system fight cancer cells.
  • RECIST: Response Evaluation Criteria In Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-free survival: The length of time during and after treatment that a patient lives without the cancer getting worse.
  • Overall survival: The length of time from the start of treatment that patients are still alive.

References